- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/045 - Cytomégalovirus
Détention brevets de la classe C07K 14/045
Brevets de cette classe: 135
Historique des publications depuis 10 ans
|
7
|
4
|
9
|
10
|
11
|
10
|
6
|
7
|
7
|
6
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Glaxosmithkline Biologicals S.A. | 1602 |
10 |
| Oregon Health & Science University | 756 |
9 |
| The Council of the Queensland Institute of Medical Research | 166 |
8 |
| Pfizer Inc. | 3413 |
6 |
| City of Hope | 1042 |
6 |
| KM Biologics Co., Ltd | 93 |
6 |
| The Regents of the University of California | 20842 |
5 |
| Variation Biotechnologies, Inc. | 59 |
5 |
| The Administrators of the Tulane Educational Fund | 409 |
3 |
| The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | 379 |
3 |
| University of Tennessee Research Foundation | 765 |
3 |
| Thelper AS | 5 |
3 |
| Novartis AG | 10175 |
2 |
| Memorial Sloan-Kettering Cancer Center | 2056 |
2 |
| Oregon Health and Science University | 54 |
2 |
| Sloan-Kettering Institute for Cancer Research | 636 |
2 |
| The UAB Research Foundation | 666 |
2 |
| The University of Birmingham | 421 |
2 |
| University of Copenhagen | 441 |
2 |
| Memorial Hospital for Cancer and Allied Diseases | 426 |
2 |
| Autres propriétaires | 52 |